Breast
Invasive ductal carcinoma of the breast
The commonest breast cancer: a hard, gritty, irregular mass fixed in the breast, which spreads first to the axillary lymph nodes; ER and HER2 status guide treatment.
Causes et facteurs de risque
- Ductal carcinoma in situ as a precursor; lobular carcinoma in situ raises the risk in either breast
Aspect macroscopique
- A firm, irregular, immobile mass with a gritty cut surface (desmoplasia and microcalcifications).
- A white, very firm (scirrhous) centre with yellow areas of necrosis.
Au microscope
- Nests and strands of tumour cells infiltrating a dense fibrous stroma.
- Perineural invasion is frequent and explains a dull, constant pain.
Évolution
- Malignant cells within ducts (ductal carcinoma in situ) break through into the stroma.
- The stroma reacts with dense fibrosis (desmoplasia): a hard, fixed lump; microcalcifications show on mammography.
- Tumour enters lymphatics and spreads to the axillary nodes first.
Complications
- Axillary lymph node metastases
- Paget disease of the nipple (intraepidermal spread) and inflammatory carcinoma (dermal lymphatics)
Examens complémentaires
- Mammography
- A spiculated (stellate) mass and microcalcifications.
- Breast and axillary ultrasound
- The mass and any enlarged axillary lymph nodes.
- Core needle biopsy
- Confirms invasive carcinoma and its grade; oestrogen and progesterone receptors and HER2 are tested.
- Sentinel lymph node biopsy
- Spread to the first draining axillary node.
Traitement médicamenteux
- Selective oestrogen receptor modulators (tamoxifen): Drugs that block oestrogen receptors in breast tissue while acting like oestrogen elsewhere: tamoxifen treats and prevents hormone receptor-positive breast cancer but raises the risk of venous thrombosis and endometrial cancer.
- Aromatase inhibitors: Drugs that block the conversion of androgens to oestrogen in fat and other tissues, the main source of oestrogen after menopause; standard treatment for hormone receptor-positive breast cancer in postmenopausal women, at a cost to bone.
- Antitumour antibiotics (anthracyclines and bleomycin): Cytotoxic drugs from Streptomyces: anthracyclines (doxorubicin) intercalate DNA and poison topoisomerase II, used in breast cancer, lymphomas and sarcomas but toxic to the heart; bleomycin breaks DNA with free radicals and scars the lungs.
- Alkylating agents (cyclophosphamide, temozolomide, dacarbazine): Drugs that attach alkyl groups to DNA, cross-linking or mispairing it; cyclophosphamide is used in breast cancer and lymphomas, temozolomide in glioblastoma, dacarbazine in Hodgkin lymphoma.
- Microtubule inhibitors (vinca alkaloids and taxanes): Drugs that disrupt the mitotic spindle so cells cannot divide: vinca alkaloids stop microtubules forming, taxanes stop them breaking down. Used in lymphomas, breast and lung cancer; neuropathy is the shared toxicity.
- HER2-targeted drugs (trastuzumab): Antibodies and kinase inhibitors aimed at the HER2 receptor, overexpressed in about a fifth of breast cancers; trastuzumab greatly improves survival in HER2-positive disease, with a risk of reversible heart dysfunction.
Anatomie concernée
Sujets liés
Rédigé d’après
- Robbins and Cotran Atlas of Pathology, 3rd ed., Ch. 14, The Breast, pp. 380–384, figs 14-29 to 14-40
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.